Rhinocerebral mucormycosis treated with posaconazole: A case report;Posakonazol ile tedavi edilen rinoserebral mukormikoz olgusu

Klimik Dergisi

Volumn 23, Issue 3, 2010, Pages 130-133

  Demiroǧlu, Yusuf Ziya ^a   Turunç, Tuba ^a   Erkan, Alper Nabi ^a   Alkan, Özlem ^a   Alişkan, Hikmet Eda ^a   Çolakoǧlu, Šule ^a   Arslan, Hande ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Mucormycosis; Posaconazole; Salvage therapy

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; POSACONAZOLE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CASE REPORT; DISEASE COURSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; ENDOSCOPIC SINUS SURGERY; FEVER; HEADACHE; HUMAN; MALE; MUCORMYCOSIS; ORBIT CELLULITIS; RHINOCEREBRAL MUCORMYCOSIS; TREATMENT FAILURE;

EID: 79251584332     PISSN: 1301143X     EISSN: 13091484     Source Type: Journal    
DOI: 10.5152/kd.2010.34     Document Type: Article

References (22)

1. Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect. 2004; 10(Suppl. 1): 31-47.
2. Sugar AM. Agents of mucormycosis and related species. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 6th ed. Philadelphia: Churchill Livingstone 2005: 2973-84.
3. Gonzalez CE, Rinaldi MG, Sugar AM. Zygomycosis. Infect Dis Clin North Am. 2002; 16(4): 895-914.
4. Bouza E, Muñoz P, Guinea J. Mucormycosis: an emerging disease?. Clin Microbiol Infect. 2006; 12(Suppl. 7): 7-23.
5. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005; 41(5): 634-53.
6. Spellberg B, Edwards J Jr, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation and management. Clin Microbiol Rev. 2005; 18(3): 556-69.
7. Khor BS, Lee MH, Leu HS, Liu JW. Rhinocerebral mucormycosis in Taiwan. J Microbiol Immunol Infect. 2003; 36(4): 266-9.
8. Nithyanandam S, Jacob MS, Battu RR, Thomas RK, Correa MA, D'Souza O. Rhino-orbito-cerebral mucormycosis. A retrosepective analysis of clinical features and treatment outcomes. Indian J Ophthalmol. 2003; 51(3): 231-6. (Pubitemid 37236912)
9. Herbrecht R. Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. Int J Clin Pract. 2004; 58(6): 612-24. (Pubitemid 38996992)
10. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother. 2002; 46(5): 1581-2.
11. Tobón AM, Arango M, Fernández D, Restrepo A. Mucormycosis (zygomycosis) in heart-kidney transplant recipient: recovery after posaconazole therapy. Clin Infect Dis. 2003; 36(11): 1488-91. (Pubitemid 36702884)
12. Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother. 2006; 50(1): 126-33.
13. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis. 2006; 42(7): e61-5.
14. Chayalkulkeeree M, Ghannoum MA, Perfect JR. Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis. 2006; 25(4): 215-29.
15. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety in 556 cases. Clin Infect Dis. 1998; 26(6): 1383-96.
16. Gleissner B, Schilling A, Anagnostopolous I, Siehl I, Thiel E. Improved outcome of zygomycosis in patients with hematological diseases? Leuk Lymphoma. 2004; 45(7): 13511-60.
17. Groll AH, Giri N, Petraitis V, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis. 2000; 182(1): 274-82. (Pubitemid 30497814)
18. Ibrahim AS, Gebremariam T, Husseiny MI, et al.Comparison of lipid amphotericin B preparations in treating murine zygomycosis. Antimicrob Agents Chemother. 2008; 52(4): 1573-6.
19. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr, Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis. 2009; 48(12): 1743-51.
20. Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008; 47(3): 364-71.
21. Sun QN, Najvar LK, Bocanegra R, Loebenberg D, Graybill JR. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother. 2002; 46(7): 2310-2.
22. Raad II, Graybill JR, Bustamante AB, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis. 2006; 42(12): 1726-34.